多Agent系统中,Agent间通过形成联盟达到提高任务求解能力,获取更多收益的目的。主要关注联盟模型的改进和联盟形成阶段的改进,基于ARG(agent,role,group)元模型和学习机制提出了一种采用角色和学习机制的新联盟模型CLAR(coalition mode...多Agent系统中,Agent间通过形成联盟达到提高任务求解能力,获取更多收益的目的。主要关注联盟模型的改进和联盟形成阶段的改进,基于ARG(agent,role,group)元模型和学习机制提出了一种采用角色和学习机制的新联盟模型CLAR(coalition model based on learnin gagent and role);在采用合同网协议的CLAR联盟模型中提出了两阶段联盟形成机制;通过捕食者问题实验验证了角色和学习机制的作用,以及两阶段联盟形成机制在减少通讯代价上的作用。展开更多
AIM:To investigate the association between TP53 Arg72Pro polymorphism and esophageal cancer(EC)risk using meta-analysis. METHODS:All eligible studies published before March 1,2010 were selected by searching PubMed usi...AIM:To investigate the association between TP53 Arg72Pro polymorphism and esophageal cancer(EC)risk using meta-analysis. METHODS:All eligible studies published before March 1,2010 were selected by searching PubMed using keywords"p53"or"TP53","polymorphism"or"variation", "esophageal"and"cancer"or"carcinoma".Crude odds ratios(ORs)with 95%confidence intervals(CIs)were assessed for EC risk associated with TP53 Arg72Pro polymorphism using fixed-and random-effects models. RESULTS:Nine case-control studies involving 5545 subjects were included in this meta-analysis.Significantly reduced risk of EC was associated with TP53genotypes for Arg/Arg+Arg/Pro vs Pro/Pro(OR= 0.73,95%CI:0.57-0.94,P=0.014).Subgroup analyses according to the source of controls and the specimens used for determining TP53 Arg72Pro genotypes or sample size showed that significantly reduced risk was observed only in studies which have populationbased controls(Arg/Arg vs Pro/Pro:OR=0.56,95% CI:0.47-0.66,P<0.001),and use white blood cells or normal tissue to assess TP53 genotypes of cases (Arg/Arg vs Pro/Pro:OR=0.56,95%CI:0.47-0.65,P <0.001)or include at least 200 subjects(Arg/Arg vs Pro/Pro:OR=0.56,95%CI:0.47-0.65,P<0.001). Analysis restricted to well-designed studies also supported the significantly decreased risk of EC(Arg/Arg vs Pro/Pro:OR=0.54,95%CI:0.46-0.64,P<0.001). CONCLUSION:TP53 Arg72 carriers are significantly associated with decreased EC risk.Nevertheless,more welldesigned studies are needed to confirm our findings.展开更多
文摘多Agent系统中,Agent间通过形成联盟达到提高任务求解能力,获取更多收益的目的。主要关注联盟模型的改进和联盟形成阶段的改进,基于ARG(agent,role,group)元模型和学习机制提出了一种采用角色和学习机制的新联盟模型CLAR(coalition model based on learnin gagent and role);在采用合同网协议的CLAR联盟模型中提出了两阶段联盟形成机制;通过捕食者问题实验验证了角色和学习机制的作用,以及两阶段联盟形成机制在减少通讯代价上的作用。
基金Supported by the National 973 Program of China(No.2004CB518605)the National 863 Project of China(No.2006AA020501)+2 种基金the National Key Sci-Tech Special Project of China(No.2008ZX10002-020)the Project of the Shanghai Municipal Science and Technology Commission(03dz14086)the National Natural Science Foundation of China(No.30024001and 30771188)
文摘AIM:To investigate the association between TP53 Arg72Pro polymorphism and esophageal cancer(EC)risk using meta-analysis. METHODS:All eligible studies published before March 1,2010 were selected by searching PubMed using keywords"p53"or"TP53","polymorphism"or"variation", "esophageal"and"cancer"or"carcinoma".Crude odds ratios(ORs)with 95%confidence intervals(CIs)were assessed for EC risk associated with TP53 Arg72Pro polymorphism using fixed-and random-effects models. RESULTS:Nine case-control studies involving 5545 subjects were included in this meta-analysis.Significantly reduced risk of EC was associated with TP53genotypes for Arg/Arg+Arg/Pro vs Pro/Pro(OR= 0.73,95%CI:0.57-0.94,P=0.014).Subgroup analyses according to the source of controls and the specimens used for determining TP53 Arg72Pro genotypes or sample size showed that significantly reduced risk was observed only in studies which have populationbased controls(Arg/Arg vs Pro/Pro:OR=0.56,95% CI:0.47-0.66,P<0.001),and use white blood cells or normal tissue to assess TP53 genotypes of cases (Arg/Arg vs Pro/Pro:OR=0.56,95%CI:0.47-0.65,P <0.001)or include at least 200 subjects(Arg/Arg vs Pro/Pro:OR=0.56,95%CI:0.47-0.65,P<0.001). Analysis restricted to well-designed studies also supported the significantly decreased risk of EC(Arg/Arg vs Pro/Pro:OR=0.54,95%CI:0.46-0.64,P<0.001). CONCLUSION:TP53 Arg72 carriers are significantly associated with decreased EC risk.Nevertheless,more welldesigned studies are needed to confirm our findings.
